MiMedx Group, Inc. (MDXG)

MiMedx Group's stock price has been impacted by several events in the past six months, including Q4 2025 and Q1 2026 earnings reports, a restructuring and cost reduction initiative, revised 2026 revenue guidance, and product launches. The company reported mixed earnings results, announced cost-saving measures, significantly cut its 2026 revenue guidance due to reimbursement headwinds, and launched new products. Over the past 12 months, the stock has lost 47.1% of its value.

Information regarding the specific demand seasonality for MiMedx Group, Inc.'s products and services is not explicitly available.

MiMedx Group, Inc. is a healthcare company specializing in regenerative medicine and advanced wound care, focusing on biomaterial products and bioimplants derived from human placental tissues. The company utilizes its patented PURION process to produce allografts for wound care, burn, and surgical sectors, with key products including EpiFix, EpiCord, AmnioFix, and others.

MiMedx Group, Inc. is headquartered in Marietta, Georgia, and primarily focuses on the United States market, selling its products through various channels. The company is also pursuing international expansion, with a small commercial presence in several international locations, particularly Japan. Other office locations include Atlanta and Kennesaw, Georgia, and Orlando, Florida.

MiMedx Group experienced challenges to its brand reputation between 2016 and 2019 due to allegations of mismanagement and financial difficulties, including the termination of its founder and delisting from NASDAQ. A cultural and financial turnaround began with the arrival of CEO Tim Wright in May 2019. Recently, the company's reputation has been influenced by its financial performance, strategic initiatives, and an investor alert from Pomerantz Law Firm.

MiMedx Group, Inc. has a diverse ownership structure, with 246 institutional owners holding a total of 106,473,912 shares. Institutional investors hold approximately 21.36% of the company's stock, while insiders own about 2.69%, and retail investors hold around 75.95%. Major institutional owners include Essex Woodlands Management, Inc., BlackRock, Inc., and Vanguard Group Inc.